Skip to main content
. 2021 Mar 3;11(3):428. doi: 10.3390/diagnostics11030428

Table 2.

Radiographic response assessment evaluating prostate-specific membrane-antigen-targeted radioligand therapy (PSMA-TV) in 21 patients compared to PERCIST and RECIST 1.1 evaluation. PD: progressive disease; SD: stable disease; PR: partial response.

PSMA-TV
PD SD PR
PERCIST PD 8 (38%) 3 (14%) 1 (5%)
SD 0 (0%) 0 (0%) 0 (0%)
PR 0 (0%) 3 (14%) 6 (29%)
RECIST 1.1 PD 7 (33%) 4 (19%) 1 (5%)
SD 1 (5%) 2 (10%) 4 (19%)
PR 0 (0%) 0 (0%) 2 (10%)